Neoleukin Therapeutics, Inc. Profile Avatar - Palmy Investing

Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic …

Drug Manufacturers - Specialty & Generic
US, Seattle [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Neoleukin Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Neoleukin Therapeutics, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Neoleukin Therapeutics, Inc..

End of NLTX's Analysis
CIK: - CUSIP: 64049K104 ISIN: US64049K2033 LEI: - UEI: -
Secondary Listings
NLTX has no secondary listings inside our databases.